ACRS Aclaris Therapeutics, Inc.: Book Valuation of Business

Public company logo of Aclaris Therapeutics, Inc. (ACRS)

The market trend for Aclaris Therapeutics (ACRS) analyzed on this chart via the GURU.Markets platform is based on the work of elite immunologists developing anti-inflammatory agents supported by stable grants. Aclaris Therapeutics (ACRS) is developing advanced methods to combat cancer and autoimmune pathologies by investing in the synthesis of protein kinase inhibitors, where the indicator stands at 0.13. The environmental profile is limited to the safe disposal of bioreagents within the framework of clinical tests.

ACRS - Aclaris Therapeutics, Inc Book Capitalization over the range 07/04/2022 - 10/30/2026

ACRS (Aclaris Therapeutics, Inc.): analytical breakdowns and indicator data

- current price and projected stock value:
Price Performance Chart Aclaris Therapeutics, Inc|ACRS - Price Target Chart
- company stock capitalization data:
Market Capitalization Aclaris Therapeutics Inc.|ACRS - Total Company Value
- book value of equity indicators:
Share Book Value Aclaris Therapeutics|ACRS - Book Capitalization|Market Value to Book Value aclaristx.com|ACRS - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Aclaris Therapeutics|ACRS - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Aclaris Therapeutics Inc.|ACRS - Company Debts|Debt to Book Value Aclaris Therapeutics Inc.|ACRS - Company Long-Term Debts|Company Short-Term Debts Aclaris Therapeutics|Intermediate Coverage Ratio aclaristx.com
- earnings and market ratios statistics:
ACRS - Net Profit
Initial company analysis:Aclaris Therapeutics
Mass-produced product of Aclaris Therapeutics Inc.

Aclaris Therapeutics (ACRS) invests in the development of unique drugs for the therapy of immune pathologies. Book capitalization calculates the net asset value by subtracting all liabilities from total assets. This metric determines the real internal reserve of the business, stripped of market noise. For a biotech company, this is an indicator of financial stability during long-term patent protection. By analyzing the history of the company's book capital, an investor can identify the fundamental development vector.

Competitor analysis for Aclaris Therapeutics

Accounting Value of Company ARGX (argenx BVBA)|BioNTech SE (BNTX) - Company Book Value|ABVX - Book Valuation of Business|Company Book Value ADMA Biologics, Inc.|Protagonist Therapeutics, Inc. - Net Asset Value|Book Capitalization IMVT|KNSA (Kiniksa Corp) - Accounting Value of Company|Book Capitalization GRFS (Grifols, S.A.)|Book Capitalization adaptivebiotech.com ADPT|CLDX - Company Book Value|Accounting Value of Company AUPH (Aurinia Pharmaceuticals Inc)|BioCryst Pharmaceuticals Inc (BCRX) - Company Book Value|Company Net Assets Vera Corp|DNTH (Dianthus Therapeutics) - Book Capitalization|Book Capitalization pharvaris.com|Company Net Assets ABCL (AbCellera Bio)|TRML (Tourmaline Bio Inc) - Accounting Value of Company|Book Capitalization PGEN (Intrexon)|Book Valuation of Business Pharming Corp (PHAR)|NKTR - Company Book Value|upstreambio.com (UPB) - Company Net Assets|Zenas Biopharma (ZBIO) - Company Book Value|Company Net Assets Immunome Inc|Company Net Assets GOSS|Book Capitalization KalVista Corp|Company Book Value Septerna Inc (SEPN)|pieris.com - Accounting Capitalization|Book Capitalization SVRA (Savara)|Rigel Pharma (RIGL) - Total Stockholders' Equity|AnaptysBio Corp - Book Capitalization|ATXS - Book Capitalization|ENGN: Book Capitalization|Company Net Assets rapt.com|Company Book Value Aerovate Therapeutics, Inc.|Company Book Value KYTX|Book Capitalization TLSA|Book Capitalization Cabaletta Bio Inc (CABA)|Company Book Value Ventyx Biosciences VTYX|Accounting Value of Company THTX|Avalo Therapeutics - Book Capitalization|Book Valuation of Business Eledon Pharmaceuticals Inc. ELDN|Agenus Inc (AGEN) - Company Book Value|CLYM - Book Valuation of Business|Company Net Assets ZURA|ATYR: Accounting Value of Company|Company Net Assets ADAG (Adagene)|Total Net Assets IMA|Book Capitalization STTK (Shattuck Labs)|Accounting Value of Company EQ|Connect Pharma - Book Capitalization|Total Stockholders' Equity Immunic, Inc.|atarabio.com (ATRA) - Company Book Value|InflaRx - Accounting Value of Company|XFOR (X4 Pharma) - Book Capitalization|Book Capitalization Adicet|Company Book Value Celularity Inc. (CELU)|INMB: Net Asset Value|Book Capitalization BRNS (Barinthus Biotherapeutics plc)|Kezar Life Sciences Inc. (KZR) - Total Stockholders' Equity|SABS: Company Net Assets|AKTX - Book Capitalization|ENLV (enlivex.com) - Company Net Assets|QTTB: Total Net Assets|GOVX (GeoVax) - Book Capitalization|Edesa Biotech Inc (EDSA) - Book Valuation of Business|Book Capitalization IBIO|Company Net Assets carismatx.com CARM|Company Book Value XTL Biopharmaceuticals XTLB|Book Valuation of Business Bolt Biotherapeutics Inc. (BOLT)|HCW Biologics Inc - Book Capitalization|APVO - Book Capitalization|AIM: Book Capitalization|Company Net Assets Aditxt, Inc.|Company Book Value GRI Bio, Inc.|XRTX: Accounting Value of Company|Company Book Value Vyome Holdings (HIND)|Book Valuation of Business Revelation Biosciences Inc|Company Book Value Indaptus INDP|SCNI (BiondVax Pharmaceuticals) - Net Asset Value|CalciMedica Corp - Book Capitalization|Accounting Value of Company AFMD (Affimed)|ALLK: Book Capitalization|HOOKIPA Pharma (HOOK) - Book Capitalization|Company Book Value IGM Biosciences Inc.|ITOS: Accounting Value of Company|Company Book Value Ocean Biomedical, Inc. (OCEA)|Company Net Assets tcbiopharm.com TCBP|Book Capitalization THRD (Third Harmonic Bio, Inc.)